Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

REGN vs BNTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

REGN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

REGN Overall Winner 6-Pillar Tally: REGN 5 – 1 BNTX Matrix Metrics: REGN 6 – 4 BNTX

As of Nov 19, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over BioNTech SE American Depositary Share (BNTX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). REGN carries a Unified Composite Score of 42.6/100 (HOLD) at $923.34 (14.9x Forward P/E, 30.4% operating margin), whereas BNTX carries 43.3/100 (HOLD) at $81.38 (7.0x Forward P/E, -55.5% operating margin).

  • Composite vs. Pillar Nuance: While BNTX currently prints a higher short-term Unified Composite Score (43.3/100 HOLD vs. REGN 42.6/100 HOLD), REGN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (30.4% vs. -55.5% operating margin) and revenue trajectory (+36.3% vs. -15.1% YoY).
  • Technical & Structure Timing Caution: REGN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.9); meanwhile BNTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About REGN vs BNTX
REGN NASDAQ Head-to-Head Winner
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$923.34
-2.35% 1D
Market Cap $97.8B
TTM Revenue $16.9B
Forward P/E 14.9x
Beta / 30D Vol 0.32β · 55% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 19.0 Fund 45.0 Flow 68.0 Mom 56.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.5% over 20 days), RSI 58
RSI-14: 57.9 · SMA20: $907.12 · SMA50: $826.97
BNTX NASDAQ
BioNTech SE American Depositary Share
Biological Products, (No Diagnostic Substances)
$81.38
-2.26% 1D
Market Cap $20.6B
TTM Revenue $2.42B
Forward P/E 7.0x
Beta / 30D Vol 0.81β · 31% Vol
Unified Composite Score
43.3 / 100 HOLD
Tech 22.0 Fund 45.0 Flow 50.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 33
RSI-14: 32.7 · SMA20: $86.68 · SMA50: $91.83

6-Pillar Scorecard Institutional Category Breakdown (REGN 5 – 1 BNTX)

Columns: Metric · REGN · BNTX
1. Valuation Multiples BNTX
Forward P/E 14.9x 7.0x
Trailing P/E 20.9x 7.0x
PEG Ratio 1.15x 0.05x
EV / Revenue 5.7x 8.5x
2. Growth & Scale REGN
Revenue Growth (YoY) +36.3% -15.1%
Earnings Growth (YoY) +35.5% -43.2%
TTM Revenue (USD) $16.9B $2.42B
Market Cap $97.8B $20.6B
3. Profitability & Quality REGN
Gross Margin 46.7% 76.7%
Operating Margin 30.4% -55.5%
Net Profit Margin 28.5% -60.9%
Return on Equity (ROE) 14.9% -8.1%
4. Balance Sheet & Cash Flow REGN
Cash Generation (TTM) $3.63B -$1.02B EBITDA
Cash Flow Margin 21.5% -42.0% EBITDA Mgn
Net Cash / Leverage $952M Net Cash $80.26 Book/Sh · -8.1% ROE
Dividend Yield 0.39% None (0.00%)
5. Options & Positioning REGN
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 35.5% (6th %ile) 41.9% (76th %ile)
Put/Call OI Skew 0.47x (Call-Skewed) Thin ADR Chain
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat REGN
OpEx & R&D Intensity 16.3% of Rev ($2.75B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: REGN (6) vs BNTX (4)
Institutional Metric REGN BNTX Criterion Row Edge
Market Capitalization
Scale
$97.8B $20.6B Larger Scale REGN
Trailing P/E Ratio
Valuation
20.9x 7.0x Lower Multiple BNTX
Forward P/E Ratio
Valuation
14.9x 7.0x Lower Multiple BNTX
Revenue Growth (YoY)
Growth
+36.3% -15.1% Higher Growth REGN
Operating Margin (TTM)
Profitability
30.4% -55.5% Higher Margin REGN
Net Profit Margin
Profitability
28.5% -60.9% Higher Margin REGN
Return on Equity (ROE)
Capital Efficiency
14.9% -8.1% Higher ROE REGN
52-Week Range Position
Momentum
83% ($592–$992) 4% ($80–$124) Stronger Trend REGN
Beta / 30D Volatility
Risk Regime
0.32β · 55% Vol 0.81β · 31% Vol Lower Realized Risk BNTX
Unified Institutional Score
Composite Signal
42.6 / 100 (HOLD) 43.3 / 100 (HOLD) Higher Composite BNTX
Trailing 12M Revenue (USD)
Operating Scale
$16.9B $2.42B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.7% 76.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.15x PEG · 5.7x EV/Rev 0.05x PEG · 8.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$3.63B ($952M Net Cash) -$1.02B EBITDA ($80.26 Book/Sh · -8.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon REGN +25.47 pp
REGN: +14.61% · BNTX: -10.86%
3M Horizon REGN +40.9 pp
REGN: +10.71% · BNTX: -30.19%
6M Horizon REGN +54.19 pp
REGN: +43.69% · BNTX: -10.5%
1Y Horizon REGN +47.93 pp
REGN: +27.3% · BNTX: -20.63%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on REGN vs BNTX. Trailing 12-month operating profitability (REGN 30.4% vs BNTX -55.5%) and valuation multiples (REGN 14.9x vs BNTX 7.0x Forward P/E) are benchmarked directly in Pillar 4 below.

REGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$16.9B
Gross Margin46.7%
Op. Margin30.4%
ROE / Fwd P/E14.9% · 14.9x
BNTX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.42B
Gross Margin76.7%
Op. Margin-55.5%
ROE / Fwd P/E-8.1% · 7.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
REGN CONSOLIDATION
55d in phase · OBV ACCUMULATION
Current IV 35.5%
IV Percentile 6th %ile
Put/Call OI Skew 0.47x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact REGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BNTX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 41.9%
IV Percentile 76th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BNTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $952.40 · IV 33.5%

REGN Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($95,240)

Compare $95,240 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 33.5% ATM IV.

5-DAY BULLISH SWING Liq C

Dec 18 $950 / $1,000 Bull Call Spread

Buy 1x $950C · Sell 1x $1,000C · 31d

Net Entry $2,387 Debit
T+5d @ +5% Move +$891 (+37%)
Max Risk / Buffer $2,387 Capped
5d Edge & Liquidity 0.8x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $880 / $820 Bull Put Spread

Sell 1x $880P · Buy 1x $820P · 59d

Net Entry $1,367 Credit
Max Credit / Yield +$1,367 (+29.5% RoM)
Max Risk / Buffer -9.0% Cushion ($4,633 Mgn)
5d Edge & Liquidity 75% PoP · Liq C
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 18 $880P / $960-$1,040C Seagull

Sell 1x $880P · Buy 1x $960/$1,040C · 31d

Net Entry $1,185 Debit
T+5d @ +5% Move +$2,220 (+15.8% RoM)
Max Risk / Buffer -7.6% Put Cushion ($14,093 Mgn)
5d Edge & Liquidity 0.8x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
REGN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $97.8B market capitalization and 30.4% operating margin.
OpEx & R&D Reinvestment 16.3% of Rev ($2.75B)
90D Engineering Disclosures 0 Published
BNTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $20.6B market capitalization and -55.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ REGN vs BNTX Key Questions & Quantitative Answers

As of Nov 19, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over BioNTech SE American Depositary Share (BNTX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). REGN carries a Unified Composite Score of 42.6/100 (HOLD) at $923.34 (14.9x Forward P/E, 30.4% operating margin), whereas BNTX carries 43.3/100 (HOLD) at $81.38 (7.0x Forward P/E, -55.5% operating margin). Composite vs. Pillar Nuance: While BNTX currently prints a higher short-term Unified Composite Score (43.3/100 HOLD vs. REGN 42.6/100 HOLD), REGN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (30.4% vs. -55.5% operating margin) and revenue trajectory (+36.3% vs. -15.1% YoY). Technical & Structure Timing Caution: REGN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.9); meanwhile BNTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

REGN leads the Growth & Scale pillar: REGN posts +36.3% YoY revenue growth and +35.5% YoY earnings growth on $16.9B TTM revenue (46.7% gross margin, 30.4% operating margin), compared with BNTX at -15.1% YoY revenue growth and -43.2% YoY earnings growth on $2.42B TTM revenue (76.7% gross margin, -55.5% operating margin). On trailing 12-month operating scale, REGN generates $16.9B in USD-normalized revenue versus $2.42B for BNTX. In operating R&D and SG&A reinvestment, REGN deploys 16.3% of Rev ($2.75B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BNTX.

BNTX screens cheaper on headline valuation multiples. REGN trades at 14.9x Forward P/E, 20.9x Trailing P/E, 1.15x PEG, and 5.7x EV/Revenue (21.5% FCF margin), whereas BNTX trades at 7.0x Forward P/E, 7.0x Trailing P/E, 0.05x PEG, and 8.5x EV/Revenue (-42.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against REGN (14.9% ROE) versus BNTX (-8.1% ROE) capital efficiency.

In options market volatility and institutional positioning, REGN carries 35.5% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.47x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.32β · 55% Vol realized risk). By comparison, BNTX carries 41.9% implied volatility (76th %ile, Elevated (60th–80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.81β · 31% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.